These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 11675918)

  • 1. [Radiotherapy and bisphosphonate therapy in bone metastases of prostate carcinoma].
    Seegenschmiedt MH; Oppenkowski R
    Praxis (Bern 1994); 2001 Sep; 90(38):1645-52. PubMed ID: 11675918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician.
    Higano CS
    Urol Clin North Am; 2004 May; 31(2):331-52. PubMed ID: 15123412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonates in prostate carcinoma.
    Adami S
    Cancer; 1997 Oct; 80(8 Suppl):1674-9. PubMed ID: 9362435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural history and treatment of bone complications in prostate cancer.
    Saad F; Clarke N; Colombel M
    Eur Urol; 2006 Mar; 49(3):429-40. PubMed ID: 16431012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer.
    Small EJ; Smith MR; Seaman JJ; Petrone S; Kowalski MO
    J Clin Oncol; 2003 Dec; 21(23):4277-84. PubMed ID: 14581438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Systemic therapy approaches in patients with bone metastases of urogenital malignancies].
    Finter F; Mottaghy FM; Kuefer R; Hautmann RE; Rinnab L
    Urologe A; 2007 Aug; 46(8):904, 906-12. PubMed ID: 17639296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bisphosphonates for cancer patients: why, how, and when?
    Body JJ; Mancini I
    Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The systemic treatment of bone metastases.
    Houston SJ; Rubens RD
    Clin Orthop Relat Res; 1995 Mar; (312):95-104. PubMed ID: 7543393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bisphosphonates in the management of prostate carcinoma metastatic to the skeleton.
    Papapoulos SE; Hamdy NA; van der Pluijm G
    Cancer; 2000 Jun; 88(12 Suppl):3047-53. PubMed ID: 10898350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of bone complications in advanced prostate cancer: rationale for bisphosphonate use and results of a phase III trial with zoledronic acid.
    Saad F
    Semin Oncol; 2002 Dec; 29(6 Suppl 21):19-27. PubMed ID: 12584691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bisphosphonates: clinical experience.
    Coleman RE
    Oncologist; 2004; 9 Suppl 4():14-27. PubMed ID: 15459426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Off-trial evaluation of bisphosphonates in patients with metastatic breast cancer.
    Liauw W; Segelov E; Lih A; Dunleavy R; Links M; Ward R
    BMC Cancer; 2005 Jul; 5():89. PubMed ID: 16048654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New generation of bisphosphonates: broad clinical utility in breast and prostate cancer.
    Rosen LS
    Oncology (Williston Park); 2004 May; 18(5 Suppl 3):26-32. PubMed ID: 15202585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical trials in metastatic breast cancer to bone: past--present--future.
    Body JJ
    Can J Oncol; 1995 Dec; 5 Suppl 1():16-27. PubMed ID: 8853520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.
    Ibrahim A; Scher N; Williams G; Sridhara R; Li N; Chen G; Leighton J; Booth B; Gobburu JV; Rahman A; Hsieh Y; Wood R; Vause D; Pazdur R
    Clin Cancer Res; 2003 Jul; 9(7):2394-9. PubMed ID: 12855610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment options for breast cancer and bone metastases.
    Pecherstorfer M
    Womens Health (Lond); 2009 Mar; 5(2):149-63. PubMed ID: 19245353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiology and treatment costs of bone metastases from lung cancer: a French prospective, observational, multicenter study (GFPC 0601).
    Decroisette C; Monnet I; Berard H; Quere G; Le Caer H; Bota S; Audigier-Valette C; Geriniere L; Vernejoux JM; Chouaid C;
    J Thorac Oncol; 2011 Mar; 6(3):576-82. PubMed ID: 21270669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone-directed treatments for prostate cancer.
    Saad F
    Hematol Oncol Clin North Am; 2006 Aug; 20(4):947-63. PubMed ID: 16861125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Biphosphonates as directed therapy in bone metastases].
    Basić-Cabaravdić H
    Med Arh; 2003; 57(1):53-7. PubMed ID: 12693348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Physiopathology, diagnosis and management of bone metastases from prostate cancer].
    Lebret T; Méjean A
    Prog Urol; 2008 Nov; 18 Suppl 7():S349-56. PubMed ID: 19070815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.